Company profile
XERIS BIOPHARMA HOLDINGS, INC.
NASDAQ:XERSBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| GVOKE HYPOPEN | approved | $22.5MQ2 2026 | 7 | approved |
| GVOKE KIT | approved | $22.5MQ2 2026 | 7 | approved |
| GVOKE PFS | approved | $22.5MQ2 2026 | 7 | approved |
| GVOKE VIALDX | approved | $22.5MQ2 2026 | 7 | approved |
| KEVEYIS | approved | $11.7MQ2 2026 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02937558 | phase2 | completed | 2016-10-01 | 2018-09-01 | Xeris Pharmaceuticals | CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism |
| NCT02733588 | phase2 | completed | 2016-03-01 | 2017-04-05 | Xeris Pharmaceuticals | Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients |
| NCT03738865 | phase3 | completed | 2018-09-27 | 2019-03-29 | Xeris Pharmaceuticals | G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes |
| NCT03439072 | phase3 | completed | 2018-01-23 | 2018-04-18 | Xeris Pharmaceuticals | G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes |
| NCT02423980 | phase2 | completed | 2015-04-01 | 2015-05-01 | Xeris Pharmaceuticals | G-Pen™ for Hypoglycemia Rescue in T1D Patients |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 212097 | 2019-09-10 | NDA | XERIS PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 011366 | 2015-08-07 | NDA | XERIS PHARMACEUTICALS INC | |||||
Loading… | ||||||||